The Difference in Serum Levels of IP-10 in Pulmonary Tuberculosis Patients with Positive AFB and AFB Conversion

Said Muchsin, Herry Priyanto, Teuku Zulfikar, Ferry Dwi Kurniawan

Abstract


Background: Tuberculosis (TB) is caused by Mycobacterium tuberculosis, which most commonly infects the lungs. Diagnostic modalities are required in smear-negative TB. IP-10 is a potent chemokine for detecting the presence of TB infection. This study aimed to determine the difference in serum IP-10 levels in patients with smear-positive pulmonary TB and pulmonary TB patients with AFB conversion after two months of therapy.

Methods: This was an analytic observational study with a cross-sectional approach. Sampling was carried out by consecutive sampling methods. AFB examination was performed using Ziehl-Neelsen staining, and serum IP-10 was measured using ELISA.

Results: The study results obtained mean IP-10 levels in TB patients with smear positive and AFB conversion after two months of treatment of 459 pg/mL and 204.4 pg/mL, respectively. Statistical analysis using independent t-test received P<0.0001. The optimal cut-off value was 306,1 pg/ml (90% sensitivity; 95% specificity; area under the curve: 0.948, 95% CI=0.88-1; P=0.0001).

Conclusion: There was a significant difference between IP-10 levels in TB patients with smear positive and AFB conversion


Keywords


AFB, IP-10, Pulmonary tuberculosis

Full Text:

PDF

References


World Health Organization. Tuberculosis [Internet]. World Health Organization. 2020 [cited 2020 Mar 25]. Available from: https://www.who.int/health-topics/tuberculosis#tab=tab_1

World Health Organization. Global tuberculosis report 2019 [Internet]. World Health Organization. Geneva; 2019. Available from: https://www.who.int/publications/i/item/9789241565714

Kementrian Kesehatan Republik Indonesia. Pusat Data dan Informasi Tuberculosis. Kementrian Kesehatan Republik Indonesia. 2018.

Metcalfe JZ, Everett CK, Steingart KR, Cattamanchi A, Huang L, Hopewell PC, et al. Interferon-γ release assays for active pulmonary tuberculosis diagnosis in adults in low-and middle-income countries: Systematic review and meta-analysis. J Infect Dis. 2011;204(SUPPL. 4):S1120–S1129.

Petrone L, Vanini V, Chiacchio T, Petruccioli E, Cuzzi G, Schininà V, et al. Evaluation of IP-10 in Quantiferon-Plus as biomarker for the diagnosis of latent tuberculosis infection. Tuberculosis (Edinb). 2018;111:147–53.

Tonby K, Ruhwald M, Kvale D, Dyrhol-Riise AM. IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection. Sci Rep. 2015;5:1–6.

Guo SJ, Jia LQ, Hu QJ, Long HY, Pang CS, Wen FQ. Diagnostic accuracy of interferon gamma-induced protein 10 for tuberculosis: A meta-analysis. Int J Clin Exp Med. 2014;7(1):93–100.

Goletti D, Petruccioli E, Joosten SA, Ottenhoff THM. Tuberculosis biomarkers: From diagnosis to protection. Infect Dis Rep. 2016;8(2):24–32.

Petrone L, Cannas A, Aloi F, Nsubuga M, Sserumkuma J, Nazziwa RA, et al. Can blood or urine IP-10 discriminate between active and no active tuberculosis in children? 2015;2015:PA3635.

Ruhwald M, Ravn P. Biomarkers of latent TB infection. Expert Rev Respir Med. 2009;3(4):387–401.

Narumi S, Takeuchi T, Kobayashi Y, Konishi K. Serum levels of IFN-inducible protein-10 relating to the activity of systemic lupus erythematosus. Cytokine. 2000;12(10):1561–5.

Ragusa F, Fallahi P. IP-10 in occupational asthma: Review of the literature and case-control study. Clin Ter. 2017;168(2):151–7.

Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO, et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 2011;22(3):121–30.

Hong JY, Jung GS, Kim H, Kim YM, Lee HJ, Cho SN, et al. Efficacy of inducible protein 10 as a biomarker for the diagnosis of tuberculosis. Int J Infect Dis. 2012;16(12):e855–9.




DOI: https://doi.org/10.36497/jri.v40i3.358

Refbacks

  • There are currently no refbacks.




Copyright (c) 2022 Jurnal Respirologi Indonesia

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


INDEXING & PARTNER

SINTA Garuda Indonesian Scientific Journal Database (ISJD) Indonesia One Search (IOS) Crossref

ROAD-ISSN Dimensions Google Scholar 

 

Jurnal Respirologi Indonesia
pISSN: 0853-7704 - eISSN: 2620-3162
Address: Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia
Phone: +62-21-2247-4845
Email: editor@jurnalrespirologi.org


An official publication by
the Indonesian Society of Respirology (ISR)

Creative Commons License
Creative Commons Attribution-NonCommercial 4.0 International License

Statcounter